Chelsea Therapeutics Reports Third Quarter 2011 Results
November 02, 2011 16:15 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Nov. 2, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) reported financial results for the third quarter 2011 and presented a quarterly update on the...
Chelsea Therapeutics Announces Preliminary Results of Interim Analysis of CH-4051 Phase II Trial in Rheumatoid Arthritis
November 02, 2011 16:00 ET
|
Chelsea Therapeutics
Mid-Range Dose of CH-4051 Demonstrates Similar Comparable Efficacy and Improved Safety and Tolerability Compared to Standard Dose of Methotrexate
Data From 0.3 mg and 1.0 mg CH-4051 Arms Suggest...
Chelsea Therapeutics to Host Conference Call to Discuss Third Quarter 2011 Results
October 27, 2011 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Oct. 27, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it will release third quarter results for the period ended September 30, 2011...
Chelsea Therapeutics Submits New Drug Application for NORTHERA(TM) (droxidopa) for the Treatment of Symptomatic NOH
September 28, 2011 07:30 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 28, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug...
Chelsea Therapeutics to Present at the 13th Annual Rodman & Renshaw Global Healthcare Investment Conference
September 07, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 7, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 13th Annual Rodman & Renshaw Global Healthcare Investment...
Chelsea Therapeutics Receives New Patent for Use of Droxidopa in Fibromyalgia
September 06, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Sept. 6, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today that the United States Patent and Trademark Office has issued U.S. Patent No....
Chelsea Therapeutics to Present at the Wedbush 2011 Life Sciences Management Access Conference
August 10, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Wedbush 2011 Life Sciences Management Access Conference at...
Chelsea Therapeutics Achieves Target Enrollment in Phase II Trial of Droxidopa in Fibromyalgia
August 08, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., Aug. 8, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has successfully reached its target enrollment of 120 patients in its Phase II trial of...
Chelsea Therapeutics Reports Second Quarter 2011 Results
July 26, 2011 16:05 ET
|
Chelsea Therapeutics
Northera™ (droxidopa) New Drug Application for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension on Track for Submission in Third Quarter 2011
Unblinded Interim Efficacy...
Preliminary Data From Exploratory Phase II Study Demonstrates Significant Activity of Droxidopa in Adult Attention Deficit Hyperactivity Disorder (ADHD)
July 26, 2011 08:00 ET
|
Chelsea Therapeutics
CHARLOTTE, N.C., July 26, 2011 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced positive top-line results of an investigator-led Phase II clinical study of...